zilebesiran investigational
Selected indexed studies
- RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial. (JAMA, 2024) [PMID:38363577]
- Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. (N Engl J Med, 2023) [PMID:37467498]
- Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial. (JAMA, 2025) [PMID:40434761]
_Worker-drafted node — pending editorial review._
Connections
zilebesiran investigational is a side effect of
Sources
- Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial. (2025) pubmed
- RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial. (2024) pubmed
- Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. (2023) pubmed
- Zilebesiran and Hypertension: A Systematic Review and Meta-analysis. (2024) pubmed
- Zilebesiran: A Novel RNA Interference Therapeutic for Hypertension. (2025) pubmed
- Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions. (2024) pubmed